Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK discusses his participation in the joint symposia regarding high risk chronic lymphocytic leukemia (CLL) and follicular lymphoma, and the use of idelalisib in treatment. Dr Davies outlines his participation in a Phase II trial to assess the efficacy and safety of idelalisib in subjects with indolent B-cell non-Hodgkin lymphoma (NHL) refractory to alkylating agents and to rituximab (NCT01282424). Results showed an overall response (OS) rate of 56%, and a median progression-free survival (PFS) of over 11 months. According to Dr Davies idelalisib gives a clear option for patients whose disease is becoming resistant to chemotherapy and antibody therapy. Further discussions involved the safety management of idelalisib and how to manage the adverse effects- such as transaminitis. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.